Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alternative RNA Splicing

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

Conservative Site-specific Recombination and Phase Variation

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...

RNA Splicing

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An exploratory study of circulating cell-free mRNAs across colorectal cancer stages.

iScience·2026

Same author

Circulating DNA reveals nucleosome occupancy patterns that are associated with nucleosome-DNA affinity and are affected in cancer.

Genome medicine·2026

Same author

Surface cues shape procoagulant properties of amyloidogenic microclots.

Cell death & disease·2026

Same author

Statistical models to characterize colon tumor stiffness heterogeneity through representative atomic force microscopy maps.

Scientific reports·2026

Same author

Post-surgery level of circulating DNA in stage III colon cancer patients: Impact on the reliability of minimal residual disease detection.

International journal of cancer·2026

Same author

Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients.

European journal of cancer (Oxford, England : 1990)·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking

Sarah Resina¹, Ryszard Kole, Adrian Travo

¹Laboratoire de Dynamique des Interactions Membranaires Normales et Pathologiques, Département de Défenses Antivirales et Antitumorales, UMR 5235 CNRS, CC 086, Université Montpellier 2, Place Eugène Bataillon, Montpellier cedex 5, France.

The Journal of Gene Medicine

|May 2, 2007

Summary

Splice-switching oligonucleotides (SSOs) delivered via DLS lipoplexes can correct aberrant splicing and restore gene expression. This novel approach offers a promising therapeutic strategy for diseases caused by splicing mutations.

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Related Experiment Videos

Last Updated: Jul 15, 2026

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

Area of Science:

Molecular Biology
Gene Therapy
RNA Therapeutics

Background:

Aberrant splicing mutations are implicated in numerous human pathologies.
Splice-switching oligonucleotides (SSOs) represent a novel therapeutic strategy to modulate aberrant mRNA splicing.
Developing efficient delivery systems for SSOs is crucial for their clinical application.

Purpose of the Study:

To optimize the delivery of splice-correcting SSOs using a liposomal system (DLS).
To evaluate the efficacy of DLS-mediated SSO delivery in correcting aberrant splicing in a cellular model.
To compare the activity of different SSO chemistries and targeting strategies.

Main Methods:

Utilized a HeLa pLuc/705 cell model with a mutated beta-globin intron affecting luciferase gene expression.
Optimized delivery of 2'-O-methyl SSOs (2'-O-Me SSO(705)) using DLS lipoplexes.
Assessed cellular and nuclear uptake of oligonucleotides via cytofluorometry and epifluorescence microscopy.
Compared the efficacy of various SSO chemistries and targeting strategies in correcting aberrant splicing.

Main Results:

DLS lipoplex-mediated delivery achieved optimal SSO activity at 100 nM, detectable as low as 10 nM.
Confirmed efficient cellular and nuclear uptake of oligonucleotides via DLS lipoplexes.
2'-O-Methoxyethyl-oligodeoxyribonucleoside phosphorothioates demonstrated superior activity compared to other SSO chemistries.
Simultaneous targeting of the splice site (705) and an enhancer region (623) was more effective than single-site targeting.

Conclusions:

DLS lipoplex-mediated SSO delivery effectively corrects aberrant splicing and restores transgene expression in HeLa cells.
This study validates DLS as a potent delivery vector for nuclear SSO delivery.
The findings present a novel and efficient approach for modulating gene expression via splice modulation.